Relevance of the thyroid hormones–αvβ3 pathway in primary myeloma bone marrow cells and to bortezomib action

References

• Moreau P, Richardson PG, Cavo M, et al. Proteasome inhibitors in multiple myeloma: 10 years later. Blood 2012;120:947–959.
   PubMed Web of Science ®Google Scholar
• Kuehl WM, Bergsagel PL. Molecular pathogenesis of multiple myeloma and its premalignant precursor. J Clin Invest 2012;122: 3456–3463.
   PubMed Web of Science ®Google Scholar
• Roca-Cusachs P, Iskratsch T, Sheetz MP. Finding the weakest link: exploring integrin-mediated mechanical molecular pathways. J Cell Sci 2012;125:3025–3038.
   Google Scholar
• Askari JA, Buckley PA, Mould AP, et al. Linking integrin conformation to function. J Cell Sci 2009;122:165–170.
   PubMed Web of Science ®Google Scholar
• Desgrosellier JS, Cheresh DA. Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer 2010; 10:9–22.
   PubMed Web of Science ®Google Scholar
• Ria R, Vacca A, Ribatti D, et al. Alpha(v)beta(3) integrin engagement enhances cell invasiveness in human multiple MM. Haematologica 2002;87:836–845.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ria R, Presta M, et al. Avb3 integrin engagement modulates cell adhesion, proliferation, and protease secretion in human lymphoid tumor cells. Exp Hematol 2001;29:993–1003.
   PubMed Web of Science ®Google Scholar
• Vacca A, Ribatti D, Presta M, et al. Bone marrow neovascularization, plasma cell angiogenic potential, and matrix metalloproteinase-2 secretion parallel progression of human multiple MM. Blood 1999;93: 3064–3073.
   PubMed Web of Science ®Google Scholar
• Bergh JJ, Lin HY, Lansing L, et al. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005;146:2864–2871.
   PubMed Web of Science ®Google Scholar
• Davis PJ, Davis FB, Mousa SA, et al. Membrane receptor for thyroid hormone: physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol 2011;51:99–115.
   PubMed Web of Science ®Google Scholar
• Cohen K, Ellis M, Khoury S, et al. Thyroid hormone is a MAPK-dependent growth factor for human myeloma cells acting via alphavbeta3 integrin. Mol Cancer Res 2011;9:1385–1394.
   PubMed Web of Science ®Google Scholar
• Sekimoto H, Eipper-Mains J, Pond-Tor S, et al. {alpha}v{beta}3 integrins and Pyk2 mediate insulin-like growth factor I activation of Src and mitogen-activated protein kinase in 3T3-L1 cells. Mol Endocrinol 2005;19:1859–1867.
   PubMed Web of Science ®Google Scholar
• Bourd-Boittin K, Le Pabic H, Bonnier D, et al. RACK1, a new ADAM12 interacting protein. Contribution to liver fibrogenesis. J Biol Chem 2008;283:26000–26009.
   PubMed Web of Science ®Google Scholar
• Iba K, Albrechtsen R, Gilpin B, et al. The cysteine-rich domain of human ADAM 12 supports cell adhesion through syndecans and triggers signaling events that lead to beta1 integrin-dependent cell spreading. J Cell Biol 2000;149:1143–1156.
   PubMed Web of Science ®Google Scholar
• Beber EH, Capelo LP, Fonseca TL, et al. The thyroid hormone receptor (TR) beta-selective agonist GC-1 inhibits proliferation but induces differentiation and TR beta mRNA expression in mouse and rat osteoblast-like cells. Calcif Tissue Int 2009;84:324–333.
   PubMed Web of Science ®Google Scholar
• Gouveia CH, Schultz JJ, Bianco AC, et al. Thyroid hormone stimulation of osteocalcin gene expression in ROS 17/2.8 cells is mediated by transcriptional and post-transcriptional mechanisms. J Endocrinol 2001;170:667–675.
   PubMed Web of Science ®Google Scholar
• Cheng S, Leonard J, Davis P. Molecular aspects of thyroid hormone actions. Endocr Rev 2010;31:139–170.
   PubMed Web of Science ®Google Scholar
• Podar K, Chauhan D, Anderson K. Bone marrow microenvironment and the identification of new targets for MM therapy. Leukemia 2009;23:10–24.
   PubMed Web of Science ®Google Scholar
• Steinbrunn T, Stuhmer T, Sayehli C, et al. Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br J Haematol 2012;159:430–440.
   PubMed Web of Science ®Google Scholar
• Ramakrishnan V, Timm M, Haug JL, et al. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2009;29:1190–1202.
   PubMed Web of Science ®Google Scholar
• Annunziata CM, Hernandez L, Davis RE, et al. A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression. Blood 2011;117:2396–2404.
   PubMed Web of Science ®Google Scholar
• Lin HY, Sun M, Tang HY, et al. L-Thyroxine vs. 3,5,3’-triiodo-L-thyronine and cell proliferation: activation of mitogen-activated protein kinase and phosphatidylinositol 3-kinase. Am J Physiol Cell Physiol 2009;296:C980–C991.
   PubMed Web of Science ®Google Scholar
• Lin HY, Tang HY, Keating T, et al. Resveratrol is pro-apoptotic and thyroid hormone is anti-apoptotic in glioma cells: both actions are integrin and ERK mediated. Carcinogenesis 2008;29:62–69.
   PubMed Web of Science ®Google Scholar
• Tang H-Y, Lin H-Y, Zhang S, et al. Thyroid hormone causes mitogen-activated protein kinase-dependent phosphorylation of the nuclear estrogen receptor. Endocrinology 2004;145:3265–3272.
   PubMed Web of Science ®Google Scholar
• Lin HY, Davis FB, Gordinier JK, et al. Thyroid hormone induces activation of mitogen-activated protein kinase in cultured cells. Am J Physiol 1999;276:C1014–C1024.
   PubMed Web of Science ®Google Scholar
• Lin HY, Shih A, Davis FB, et al. Thyroid hormone promotes the phosphorylation of STAT3 and potentiates the action of epidermal growth factor in cultured cells. Biochem J 1999;338:427–432.
   PubMed Web of Science ®Google Scholar
• Scarlett A, Parsons MP, Hanson PL, et al. Thyroid hormone stimulation of extracellular signal-regulated kinase and cell proliferation in human osteoblast-like cells is initiated at integrin alphaVbeta3. J Endocrinol 2008;196:509–517.
   PubMed Web of Science ®Google Scholar
• Lin H, Tang H, Shih A, et al. Thyroid hormone is a MAPK-dependent growth factor for thyroid cancer cells and is anti-apoptotic. Steroids 2007;72:180–187.
   PubMed Web of Science ®Google Scholar
• Davis F, Tang H, Shih A, et al. Acting via a cell surface receptor, thyroid hormone is a growth factor for glioma cells. Cancer Res 2006;66:7270–7275.
   PubMed Web of Science ®Google Scholar
• Eliceiri BP, Klemke R, Stromblad S, et al. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis. J Cell Biol 1998;140:1255–1263.
   PubMed Web of Science ®Google Scholar
• Mulgrew K, Kinneer K, Yao XT, et al. Direct targeting of alphavbeta3 integrin on tumor cells with a monoclonal antibody, Abegrin. Mol Cancer Ther 2006;5:3122–3129.
   PubMed Web of Science ®Google Scholar
• Teti A, Migliaccio S, Baron R. The role of the alphaVbeta3 integrin in the development of osteolytic bone metastases: a pharmacological target for alternative therapy? Calcif Tissue Int 2002;71:293–299.
   PubMed Web of Science ®Google Scholar
• Tucci M, De Palma R, Lombardi L, et al. beta(3) Integrin subunit mediates the bone-resorbing function exerted by cultured myeloma plasma cells. Cancer Res 2009;69:6738–6746.
   PubMed Web of Science ®Google Scholar
• Cody V, Davis PJ, Davis FB. Molecular modeling of the thyroid hormone interactions with alpha v beta 3 integrin. Steroids 2007; 72:165–170.
   PubMed Web of Science ®Google Scholar
• Dresner-Pollak R, Rosenblatt M. Blockade of osteoclast-mediated bone resorption through occupancy of the integrin receptor: a potential approach to the therapy of osteoporosis. J Cell Biochem 1994;56: 323–330.
   PubMed Web of Science ®Google Scholar
• McLane MA, Vijay-Kumar S, Marcinkiewicz C, et al. Importance of the structure of the RGD-containing loop in the disintegrins echistatin and eristostatin for recognition of alpha IIb beta 3 and alpha v beta 3 integrins. FEBS Lett 1996;391:139–143.
   PubMed Web of Science ®Google Scholar
• Lin HY, Davis PJ, Tang HY, et al. The pro-apoptotic action of stilbene-induced COX-2 in cancer cells: convergence with the anti-apoptotic effect of thyroid hormone. Cell Cycle 2009;8: 1877–1882.
   PubMed Web of Science ®Google Scholar
• Glinskii AB, Glinsky GV, Lin HY, et al. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 2009;8:3554–3562.
   Web of Science ®Google Scholar
• Rebbaa A, Chu F, Davis FB, et al. Novel function of the thyroid hormone analog tetraiodothyroacetic acid: a cancer chemosensitizing and anti-cancer agent. Angiogenesis 2008;11:269–276.
   PubMed Web of Science ®Google Scholar
• Yalcin M, Bharali DJ, Lansing L, et al. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res 2009;29:3825–3831.
   PubMed Web of Science ®Google Scholar